PARP inhibitors in the management of breast cancer: current data and future prospects

被引：206

作者：

Livraghi, Luca ^{[1
]}

Garber, Judy E. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

来源：

BMC MEDICINE | 2015年 / 13卷

关键词：

BRCA; Breast cancer; PARP inhibitors; Poly(ADP-ribose) polymerases; POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; RECOMBINATION DEFICIENCY HRD; RECURRENT EPITHELIAL OVARIAN; REFRACTORY SOLID TUMORS; PHASE-1; DOSE-ESCALATION; EPOTHILONE-B ANALOG; II CLINICAL-TRIAL; DNA-REPAIR DEFECT; BRCA MUTANT-CELLS; HOMOLOGOUS RECOMBINATION;

D O I：

10.1186/s12916-015-0425-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Poly(ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage repair. Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA-damage repair, including BRCA1 and BRCA2 mutation-associated breast and ovarian cancers. Several PARP inhibitors are currently in trials in the adjuvant, neoadjuvant, and metastatic settings for the treatment of ovarian, BRCA-mutated breast, and other cancers. We herein review the development of PARP inhibitors and the basis for the excitement surrounding these agents, their use as single agents and in combinations, as well as their toxicities, mechanisms of acquired resistance, and companion diagnostics.

引用

页数：16

共 127 条

[51] Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells [J].

Ha, Kyungsoo ;

Fiskus, Warren ;

Choi, Dong Soon ;

Bhaskara, Srividya ;

Cerchietti, Leandro ;

Devaraj, Santhana G. T. ;

Shah, Bhavin ;

Sharma, Sunil ;

Chang, Jenny C. ;

Melnick, Ari M. ;

Hiebert, Scott ;

Bhalla, Kapil N. .

ONCOTARGET, 2014, 5 (14) :5637-5650

[52] Hallmarks of Cancer: The Next Generation [J].

Hanahan, Douglas ;

Weinberg, Robert A. .

CELL, 2011, 144 (05) :646-674

[53] The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings [J].

Helleday, Thomas .

MOLECULAR ONCOLOGY, 2011, 5 (04) :387-393

[54]

Hoosier Cancer Research Network, PARP INH TRIPL NEG B

[55] A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer. [J].

Isakoff, S. J. ;

Overmoyer, B. ;

Tung, N. M. ;

Gelman, R. S. ;

Habin, K. ;

Qian, J. ;

Giranda, V. ;

Shepherd, S. ;

Garber, J. E. ;

Ellisen, L. W. ;

Winer, E. P. ;

Goss, P. E. .

CANCER RESEARCH, 2011, 71

[56]

Isakoff S.J., 2010, J Clin Oncol, V28, P1019, DOI DOI 10.1200/JCO.2010.28.15_SUPPL.1019

[57] Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors [J].

Jaspers, Janneke E. ;

Kersbergen, Ariena ;

Boon, Ute ;

Sol, Wendy ;

van Deemter, Liesbeth ;

Zander, Serge A. ;

Drost, Rinske ;

Wientjens, Ellen ;

Ji, Jiuping ;

Aly, Amal ;

Doroshow, James H. ;

Cranston, Aaron ;

Martin, Niall M. B. ;

Lau, Alan ;

O'Connor, Mark J. ;

Ganesan, Shridar ;

Borst, Piet ;

Jonkers, Jos ;

Rottenberg, Sven .

CANCER DISCOVERY, 2013, 3 (01) :68-81

[58] Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition [J].

Johnson, Neil ;

Li, Yu-Chen ;

Walton, Zandra E. ;

Cheng, Katherine A. ;

Li, Danan ;

Rodig, Scott J. ;

Moreau, Lisa A. ;

Unitt, Christine ;

Bronson, Roderick T. ;

Thomas, Huw D. ;

Newell, David R. ;

D'Andrea, Alan D. ;

Curtin, Nicola J. ;

Wong, Kwok-Kin ;

Shapiro, Geoffrey I. .

NATURE MEDICINE, 2011, 17 (07) :875-U257

[59] Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation [J].

Kaufman, Bella ;

Shapira-Frommer, Ronnie ;

Schmutzler, Rita K. ;

Audeh, M. William ;

Friedlander, Michael ;

Balmana, Judith ;

Mitchell, Gillian ;

Fried, Georgeta ;

Stemmer, Salomon M. ;

Hubert, Ayala ;

Rosengarten, Ora ;

Steiner, Mariana ;

Loman, Niklas ;

Bowen, Karin ;

Fielding, Anitra ;

Domchek, Susan M. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) :244-250

[60] A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours [J].

Khan, O. A. ;

Gore, M. ;

Lorigan, P. ;

Stone, J. ;

Greystoke, A. ;

Burke, W. ;

Carmichael, J. ;

Watson, A. J. ;

McGown, G. ;

Thorncroft, M. ;

Margison, G. P. ;

Califano, R. ;

Larkin, J. ;

Wellman, S. ;

Middleton, M. R. .

BRITISH JOURNAL OF CANCER, 2011, 104 (05) :750-755

← 1 2 3 4 5 6 7 8 9 10 →